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This article describes the development of nanostructured lipid
carriers (NLC) as colloidal carriers for two antitumor compounds
that possess a remarkable antineoplastic activity. But their limited
stability and low solubility in water could give a very low parenteral
bioavailability. Results revealed an enhancement of the cytotoxicity
effect of drug-loaded NLC on human prostate cancer (PC-3) and
human hepatocellular carcinoma (HuH-6, HuH-7) cell lines with
respect to that of both free drugs. Results of characterization stud-
ies strongly support the potential application of these drugs-loaded
NLC as prolonged delivery systems for lipophilic drugs by several
administration routes, in particular for intravenous administra-
tion.
Keywords Antitumor Drugs, Controlled Release, Human Hepatocel-
lular Carcinoma Cells, Human Prostate Carcinoma Cells,
Nanostructured Lipid Carrier.
Colloidal carriers offer a great number of potential advantages
as drug delivery systems, such as an improvement of bioavail-
ability of poorly water-soluble drugs, resulting in an increased
drug half life that reflects in an enhanced therapeutic perfor-
mance (1). Great attention currently is paid to lipid particles with
submicron size, the so-called solid lipid nanoparticles (SLN),
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due to their biodegradability and ability to entrap a great variety
of biologically active compounds (2,3). SLN combine the ad-
vantages of other innovative colloidal carrier systems, such as
liposomes and polymeric nanoparticles (e.g., physical stability,
protection of incorporated labile compounds from degradation,
controlled release of drug) while at the same time minimize their
associate problems as toxicity of materials and difficulties in up-
scaling (4–6). More recently, modification of SLN, the so-called
nanostructured lipid carriers (NLC), has been reported (7,8).
Such modifications overcome limitations of conventional SLN,
such as unexpected dynamics of polymorphic transitions and in-
herently low drug incorporation capacity due to the crystalline
structure of the solid lipid (9,10). NLC can be realized by mixing
spatially different lipids or liquid lipids (oils) with solid lipids.
In the latter case, if a proper amount of oil is mixed with the solid
lipid, a phase separation and the formation of oily nanocompart-
ments within the solid lipid matrix can occur (11,12). This leads
to the possibility of incorporating a high amount of drug inside
these systems, because liquid lipids solubilize drugs to a much
higher extent than solid lipids (13). Moreover, control of drug
release can be obtained due to encapsulating solid lipid (13).
8-cyano-6-phenyl-7-methyl-3-(para-chlorophenyl)-[2,1-d]-
pyrrolo-[1,2,3,5]tetrazine-4-one (compound A) and 8-cyano-
3,6-diphenyl-7-methyl-[2,1-d]-pyrrolo-[1,2,3,5]tetrazine-4-one
(compound B), compounds that hold the deaza skeleton of the
antitumor drug temozolomide
©R , were synthesized (14). Such
compounds were tested at the National Cancer Institute of
Bethesda against 60 human cell lines that have grouped in dis-
ease subpanels including leukemia, nonsmall-cell lung, colon,
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central nervous system, melanoma, ovarian, renal, prostate, and
breast tumors or cell lines. Details of this in vitro test system
and the information, encoded by the activity pattern over all cell
lines, have been reported previously (15–17). The antitumor
activity of test compounds is given by three parameters for
each cell line; pGI50 value (GI50 is the molar concentration of
the compound that inhibits 50% net cell growth); pTGI (TGI
is the molar concentration of the compound leading to total
inhibition of the net cell growth); and pLC50 value (LC50 is
the molar concentration of the compound that induces 50%
net cell death). Moreover, a mean graph midpoint (MG MID)
is calculated for each of the mentioned parameters, giving an
average activity parameter over all cell lines. For the calculation
of the MG MID, insensitive cell lines are included with the
highest concentration tested.
Both pyrrolotetrazinones were shown to be active against all
the human cell lines tested with GI50 values at micromolar or
submicromolar concentrations and, in the case of compound
A, even at nanomolar level (18). Compounds A and B possess
extremely hydrophobic behavior, and for this reason their use in
conventional dosage forms could be limited.
Compound B was evaluated as anticancer agent in an in vivo
animal model in which polyvinylidene fluoride (PVDF) hol-
low fibers containing various human cancer cell cultures were
implanted intraperitoneally (ip) and subcutaneously (sc) into
mice (19). The effects of the compound on reduction of vi-
able cancer cell mass compared with those of controls were
determined. Compound B was tested in the hollow fibre assay
against a panel of 12 human cell lines (non-small cell lung can-
cer: NCI-H23, NCI-H522; colon cancer: SW-620, COLO-205;
CNS cancer: U251, SF-295; melanoma: LOX IMVI, UACC-62;
ovarian cancer: OVCAR-3, OVCAR-5; breast cancer: MDA-
MB-231, MDA-MB-435), as described previously (19,20). The
compound was solubilized in 10% DMSO in saline/Tween-80R
and administrated ip once daily for a total of 4 doses at each of
two dose levels (150 and 100 mg/Kg). The day after the admin-
istration of the last compound dose, the fibers were collected
and assessed for viable cell mass. Unfortunately, compound B
was inactive under the conditions of test, in spite of the fact that
in the in vitro tests against the same cell lines, it showed remark-
able antiproliferative activity (GI50 1.47·10−5 – 1.77·10−7) (18).
Probably it decomposed before reaching the target.
Thus the formulation of pyrrolotetrazinones as drug delivery
systems can be advantageous, considering that nanoparticulate
systems such as NLC have been proposed for administration of
drugs in cancer therapy. In fact, a critical advantage in treat-
ing tumors with nanoparticulate systems comes from the unique
pathophysiological characteristics of solid tumors: extensive an-
giogenesis and hence hypervascularization, coupled with poor
lymphatic drainage, which allow a facilitate extravasation into
the tumor and an enhanced permeation and retention effect (EPR
effect) of colloidal systems (21–24). For this reason, nanoparti-
cles such as NLC are intriguing since they are able to increase
drug levels within the tumor by circumventing the tumor vascu-
lature, to decrease normal tissue toxicities by reducing the level
of drug in the systemic circulation, and to act as depot for the
extended release of drug (21). However, the accumulation of
lipid nanoparticles within the Kuppfer cells of the liver gener-
ally is found after intravenously injection. With the exception of
liver diseases like hepatic neoplasms and liver infections, pas-
sive liver targeting can be easily avoided by modulating their
physicochemical characteristics as particle size, surface charge,
and surface hydrophobicity (7,25).
Our article describes the development of NLC loaded with
compounds A and B as potential carriers for drug administra-
tion in cancer treatment. The preparation and the characteriza-
tion of empty and drug-loaded NLC regarding loading capacity,
size, shape and zeta potential values are described. Drug re-
lease studies in human plasma and viability assays against three




pyrrolo-[1,2,3,5]tetrazine-4-one (compound A) and 8-cyano-
3,6-diphenyl-7-methyl-[2,1-d]-pyrrolo-[1,2,3,5]tetrazine-4-one
(compound B) were prepared according to the procedure re-
ported in literature [14] by reacting 3-cyano-4-methyl-5-phenyl-
2-diazopyrrole with 4-chloro-phenyl- and phenyl-isocyanate
for compounds A and B, respectively: to a solution of the
diazo compound (2 mmol) in dry dimethylformamide (10 ml),
the suitable isocyanate (20 mmol) in dry dimethylformamide
(10 ml) was added dropwise, at room temperature, in the
dark. The reaction mixture was stirred until the diazo band at
∼2110 cm−1 disappeared (24–72 hr), then poured onto crushed
ice. The solid precipitate was filtered off, air dried, and purified
by flash chromatography with dichloromethane as eluant to
give the desired compounds.
Compritol 888 ATO (mixture of approximately mono-, di-
and triglycerides of behenic acid, at 15, 50 and 35% w/w,
respectively) was a gift of Gattefossé s.a. (Saint-Priest, France).
Miglyol 812 (caprylic/capric triglycerides, medium chain
triglyceride) was supplied by Sasol GmbH (Germany). Soy
phosphatidylcholine 95% (Epikuron 200) was donated by De-
gussa Texturant Systems (Germany). Taurocholic acid sodium
salt was purchased from Sigma-Aldrich (Milan, Italy). The other
chemicals were of obtained from Sigma and were of analytical
grade.
Preparation of Empty NLC
NLC were prepared through the precipitation technique.
The lipid phase was prepared by melting Compritol 888 ATO
(150 mg) at 85˚C and then adding Miglyol 812 (30 mg).
Epikuron 200 (36 mg) was solubilized in ethanol (2 ml) at 85˚C
and then the melted lipid phase was added under stirring. NLC
were obtained by dispersing the obtained warm solution in cold
water at 2–3˚C (100 ml) containing taurocholate sodium salt
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(130.7 mg), by using an Ultra Turrax T25 (IKA, D-Staufen).
The obtained NLC dispersion was submitted to exhaustive dial-
ysis by using Visking Tubing Dialysis 18/32” (with a molecular
weight cut-off of 12,000–14,000). The NLC dispersion were
freeze-dried using a Modulyo freeze-dryer (Edwards, Crawley,
UK).
Preparation of Drug-Loaded NLC
The lipid phase was prepared by heating Compritol 888 ATO
(150 mg) at 85˚C and adding Miglyol 812 (30 mg). Epikuron
200 (36 mg) was solubilized in ethanol (2 ml) at 85˚C and then
the melted lipid phase was added under stirring. The compound
(A or B) was added to the hot solution and the solution was
left for 10 min under mechanical stirring. A-loaded NLC and
B-loaded NLC were obtained by dispersing the obtained warm
solution in cold water at 2-3˚C (100 ml) containing taurocholate
sodium salt (130.7 mg), by using an Ultra Turrax. The drug-
loaded NLC dispersions were submitted to exhaustive dialysis
and then freeze-dried.
Characterization of Empty and Drug-Loaded NLC
Particle Size Determination
The average diameter and polydispersity index of empty
and drug-loaded NLC were determined by photon correlation
spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern In-
strument, Herrenberg, Germany) that utilizes the Non-Invasive
Back-Scattering (NIBS) technique. Each sample was appropri-
ately diluted with filtered water (0.2 μm) and the reading was
carried at a 173˚ angle in respect to the incident beam. Each
reported value was the average of three measurements.
Zeta Potential Measurements
The zeta potential values were measured using principles of
laser doppler velocimetry and phase analysis light scattering
(M3-PALS technique). For this purpose, a Zetasizer Nano ZS
Malvern Instrument equipped with a He-Ne laser at a power
P = 4.0 mW and with λ = 633 nm was used (Herrenberg,
Germany). Empty and drug-loaded NLC samples were dispersed
in filtered (0.2 μ m) double-distilled water, in an aqueous solu-
tion of NaCl (0.9% w/v) or in phosphate buffer at pH 7.4. Each
sample was analyzed in triplicate.
HPLC Analysis of Compounds A and B
An adequate HPLC method was developed to study drug
loading and release process of A and B. The HPLC analysis
was performed at room temperature using a Shimatzu instru-
ment equipped with a reversed-phase C18 column (μ Bondapak,
3 μm, 150 × 4.6 mm i.d., Supelco). A mixture of CH3OH and
H2O (80:20 v/v) with a flow rate of 0.4 ml min−1 was used as
mobile phase. The HPLC column system was connected with a
UV-Vis detector (Shimatzu). A and B, either fresh or released
from NLC, were injected and measured at the wavelength of
360 nm.
Quantification of each compound was done by using a cal-
ibration curve obtained using solutions at known drug concen-
trations. The straight-line equation for compound A was:
y = 58380x − 136292 (y = peak area;
x = drug concentration μgml−1) [1]
The linear regression value was r = 0,9984. The linearity of the
method was studied in the range 25–100 μg ml−1.
The straight-line equation for compound B was:
y = 51437x − 108612 (y = peak area;
x = drug concentration μgml−1) [2]
The linear regression value was r = 0,9996. The linearity of the
method was studied in the range 25–100 μg ml−1.
Determination of Loading Capacity
The loading capacity of NLC, expressed as amount of loaded
drug in percent related to the lipid phase (matrix lipid + drug),
was calculated using the following procedure. Typically, 5 mg
of each batch of freeze-dried drug-loaded NLC were solubi-
lized in 5 ml of dichloromethane. The organic solution was fil-
tered through 0.45 μm (PTFE membrane) filters and analyzed
by HPLC to determine the amount of compounds.
Release of A and B from NLC in Human Plasma
Release of A and B from NLC samples was assayed at 7 pre-
fixed time intervals. Seven suspensions of each batch containing
10 mg of drug-loaded NLC in 5 ml of human plasma were pre-
pared and kept at 37˚C ± 0.1˚C under mechanical stirring. At
fixed time intervals, each sample was centrifuged at 13000 g
for 10 min at 4˚C. Then 2-propanol (4 ml) was added to 1 ml
of supernatant and the obtained suspension was centrifuged at
13000 g for 5 min at 4˚C. Then supernatant was assayed by
HPLC.
Cell Viability Assays
All experiments were conducted using human hepatocellu-
lar carcinoma (HuH-6, HuH-7) cells and human prostate cancer
(PC-3) cells. HuH-6 and HuH-7 cell lines were grown as a mono-
layer in RPMI 1640 medium (Sigma, Milan, Italy) supplemented
with 10% heat-inactivated fetal calf serum (Invitrogen, Milan,
Italy), 2 mmol/l L-glutamine, 1 mmol/l sodium pyruvate, and
penicillin/streptomycin solution (100 units/ml) (all from Sigma),
at 37˚C in 5% CO2 humidified atmosphere. They were subcul-
tured after trypsinization (with 0.05% trypsin/0.02% EDTA in
PBS, from Sigma) for 5 min at room temperature, washing and
suspended again in complete medium. The human prostate PC-3
cell line was maintained as above unless that sodium pyruvate
was omitted.
Cells in complete medium were seeded on 96-well plates at a
density of 5,000 per well and allowed to adhere overnight. Before
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TABLE 1
Dimensional analysis by photon correlation spectroscopy and loading capacity of A- and B-loaded NLC prepared by
precipitation method.
Polydispersity Loading capacity
Size (nm) Index (% w/w)
Empty NLC 116.1 ± 0.7 0.240 ± 0.005 —
A-loaded NLC 122.3 ± 0.9 0.148 ± 0.030 21.0 ± 0.13
B-loaded NLC 126.2 ± 1.1 0.172 ± 0.011 19.2 ± 0.11
Each value is the mean of three experiments ± S.E.
use, empty or drug-loaded NLC suspension in double distilled
water (1 mg/ml) was freeze-dried. Then, freeze-dried empty and
drug-loaded NLC samples were dispersed in the proper medium
using a water bath sonication for 10 min (Transsonic 310, Elma,
Germany).
At time 0, the cell medium was replaced with fresh
complete medium, and various concentrations (0.1–5 μM)
of A or B, free in DMSO solution or blended in NLC, were
added and cells were cultured for 72 hrs. Unloaded NLC
toxicity also was evaluated on the three cell lines growth at
the highest concentrations corresponding to that of 5 μM of
A- or B-loaded NLC. At the end of incubation, MTT assay
was performed using the CellTiter Aqueous OneSolution
kit (Promega Corporation, Madison, WI, USA) containing
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulphophenyl)-2H-tetrazolium (MTT) and phenazine etho-
sulfate. Briefly, 15 μl of the above mentioned commercial
solution were added to each well. The plates were incubated
for 1 h in a humidified atmosphere at 37˚C in 5% CO2. The
bioreduction of the MTT dye was assessed by measuring the
absorbance of each well at 490 nm. Cytotoxicity was expressed
as a percentage of the absorbance measured in the control
cells (100%). Experiments were performed in triplicate, with
the results reflecting the mean and standard deviation of the
triplicate of each group.
RESULTS AND DISCUSSION
In our study, nanostructured lipid carriers (NLC) empty and
loaded with two antitumor compounds (A and B) were pre-
TABLE 2
Zeta potential values (mV) of empty and drug-loaded NLC
H2O NaCl PBS (pH 7.4)
Empty NLC −32.22 ± 1.0 −11.19 ± 0.7 −14.51 ± 1.7
A-loaded NLC −33.57 ± 1.8 −9.11 ± 1.8 −13.26 ± 1.5
B-loaded NLC −31.07 ± 0.3 −8.11 ± 0.6 −11.73 ± 1.1
Each value is the mean of three experiments ±S.E.
H2O = Double-distilled water, NaCl = sodium chloride.
PBS = phosphate buffered solution.
pared successfully by the precipitation technique. In these sys-
tems, solid and liquid lipids were blended to form a solid matrix
that contains liquid oily nanocompartments to accommodate the
drugs.
Drug Loading and Size Analysis
These systems were characterized in terms of drug loading ca-
pacity and particle size distribution to investigate whether these
possess the best characteristics to be used as a colloidal pharma-
ceutical formulation for parenteral administration of drugs. In
Table 1, loading capacity (% w/w), size (nm), and polydisper-
sity index (P.I.) are reported. The data indicate that the average
diameter of empty and drug-loaded NLC batches were quite
small and in the range of 110 to 130 nm, with the empty system
smaller than drug-loaded NLC. This result probably is due to a
higher amount of lipid phase, containing also the drug, precipi-
tated in the aqueous cold phase for obtaining drug-loaded NLC.
The quite low P.I. values also indicate a good dimensional ho-
mogeneity of the prepared systems. B-loaded NLC were found
to be the largest (about 126 nm) since the amount of entrapped
compound is lower than A-loaded one.
However, the loading capacity, determined by HPLC analysis
and expressed as the percentage ratio between the weight of
compound entrapped and the total weight of NLC, results are
very high in both the A- and B-loaded samples, at 21.0 and
19.2% w/w, respectively. These results appear important because
these characteristics after the possibility of administering these
systems loaded with a considerable amount of drug due to small
size by all the possible routes.
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Zeta Potential Measurements
To investigate the surface charge of empty and drug-loaded
NLC, zeta potential measurements were carried out in three dif-
ferent aqueous media. Table 2 shows the zeta potential values of
empty and drug-loaded NLC batches.
The surface charge values are negative for both empty and
drug-loaded samples in all the investigated media. Moreover,
these values are higher in double-distilled water ranging be-
tween −31 and −34 mV. The presence of electrolytes causes
a diminution of surface charge of all the investigated samples.
However, using the same dispersing medium, no statistically
significant differences were found between various examined
batches. The presence of a charge onto the surface is important
because it makes these systems more stable when dispersed into
an aqueous solution, reducing the occurrence of the aggregation
phenomenon.
Release Studies in Human Plasma
To evaluate the controlled release potentiality of the investi-
gated NLC, in vitro release studies were carried out in human
plasma. Figure 1 shows the percentage amount of compound
(A or B) released from NLC samples as function of incubation
time.
Experimental results for both A and B compounds showed
an initial low burst effect (11% and 18%, respectively, of com-
pound released after 15 min of incubation) and a release con-
siderably slow during the investigation time. In fact, less than
30% and 38% of A and B, respectively, were released from NLC
within 24 hr incubation. After 24 hr of incubation loaded sam-
ples were analyzed and both unreleased compounds were found
into nanoparticles. This fact is very important considering that
loaded NLC will release in the bloodstream a low percentage of
loaded compounds that could reach the target site (as a tumor)
FIG. 1. Release profiles of A () and B () from drug-loaded NLC in human
plasma. Each value is the mean of three experiments. All calculated standard
devintions were less than 3% of the mean values and thus not reported.
FIG. 2. Effects of A (•) and A-loaded NLC (◦) on the viability of HuH-6 (a),
HuH-7 (b), and PC-3 (c) cells. Cells were grown and treated for 72 hr. Ex-
periments were performed in triplicate, with the results showing the mean and
standard deviation of the triplicate of each group. The experiments were repeated
three times with similar results.
66 M. L. BONDÌ ET AL.
inside of the lipid carrier and there it could be released. These
systems, which possess surface and dimensional characteristics
useful for parenteral administration, are able to give a prolonged
release of compounds A and B.
Viability Assays
To evaluate the activity of compounds A and B when adminis-
tered as free forms or loaded in NLC, in vitro cytotoxicity assays
were carried out on human hepatocellular carcinoma (HuH-6,
HuH-7) and on human prostate cancer (PC-3) cell lines by us-
ing the MTT test. To ensure that the cytotoxicity was caused
by the compound itself and not by formulation components of
NLC, cells were incubated with unloaded nanoparticles. No cy-
totoxicity of the unloaded NLC was observed after 72 hr on
the three cell lines studied, even at the highest concentration
(not shown), indicating the absence of cytotoxicity of empty
NLC or any material released from them at the conditions used
for experiments. Figure 2 shows the survival curves of HuH-6
(Figure 2A), HuH-7 (Figure 2B), and PC-3 (Figure 2C) cells
after exposure to free A and A-loaded NLC. The effect of B and
B-loaded NLC was tested only on HuH-6 cells and reported in
Figure 3.
The data indicate that the cytotoxicity of compounds, both in
the free form and blended in NLC, on all the cell lines tested in-
crease in a dose-dependent manner in the presence of either A or
B. Moreover, the incorporation of compounds into the lipid car-
rier seems to enhance the cytotoxicity effect of both compounds
on tested cells. This fact is very important since these compounds
are not freely soluble in water, and the result can be explained
by incorporation within a lipid carrier probably enhances the
penetration of compounds inside the cell by processes such as
FIG. 3. Effects of B (•) and B-loaded NLC (◦) on the viability of HuH-6
cells. Cells were grown and treated for 72 hr. Experiments were performed
in triplicate, with the results showing the mean and standard deviation of the
triplicate of each group. The experiments were repeated three times with similar
results.
endocytosis. Moreover, nanoparticles once in the bloodstream
are mostly recognized by macrophages of the liver and other
organs of the reticuloendotelial system, making these systems
potentially useful for drug passive targeting for the treatment of
hepatic neoplasms.
CONCLUSION
In this study the utility of NLC dispersions as carriers for
parenteral delivery of antitumor drugs was explored. NLC,
constituted of bioacceptable lipids, were prepared by the precip-
itation technique as empty systems or drug-loaded with two an-
titumoral pyrrolotetrazinones, A and B. Empty and drug-loaded
NLC showed average diameters in the colloidal size range, a
spherical shape, a good loading capacity, and a prolonged drug
release of both compounds in human plasma. In vitro cytotox-
icity assays on human hepatocellular carcinoma (HuH-6 and
HuH-7) and on human prostate cancer (PC-3) cell lines have
shown that the incorporation of compounds A and B into the
lipid carrier enhance the cytotoxicity effect of both compounds
on tested cells.
Results of characterization strongly support the potential ap-
plication of both A- and B-loaded NLC as a drug delivery system
for controlled release by several administration routes.
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